Kraft Prize Symposium

Jonathan Kraft Prize for Excellence in Cancer Research
Presented by the Massachusetts General Hospital Cancer Center

Overview & Agenda

2018 Jonathan Kraft Prize for Excellence in Cancer Research

Thursday, May 3, 2018 | 1:00pm-5:00pm
Starr Center, Simches Building, 2nd Floor
185 Cambridge Street
Boston, MA 02114

Register

View Speakers & Agenda

Download Event Flyer


Since 2006, the MGH Center for Cancer Research has annually honored a luminary in the field - an extraordinary scientist, who has made major advances in our understanding of cancer and its treatment, and has been recognized as a true mentor by teaching and inspiring the next generation of cancer researchers. This year, the 2018 Kraft award will be presented to Charles Swanton, MD, PhD, of the Frances Crick Institute and Cancer Research-UK, for his outstanding work that has led to insight into genomic diversity within cancers and molecular mechanisms driving cancer evolution. Previous recipients of the MGH Award in Cancer Research (preceding the endowment of this award in honor of Jonathan Kraft) include: Drs. Anton Berns, Joan Massague, Titia de Lange, Bert Vogelstein, Charles Sawyers, Michael Stratton, Craig Thompson, James Allison, and Hans Clevers. In 2015 Dr. David Allis was the first recipient of the named Jonathan Kraft Award. In 2016, the Award was given to Dr. Joan Steitz, and last year it was presented to Dr. Kevan Shokat.


Agenda


1:00pm - Welcome, Opening Remarks, and Introductions


1:10pm - "Clonal heterogeneity and evolution of brain tumors"

        • Raul Rabadan, PhD

          Professor of Systems Biology and Biomedical Informatics
          Director of Mathematical Genomics
          Columbia University

  • View Bio

    Dr. Raul Rabadan is a Professor in the Department of Systems Biology and Biomedical Informatics at Columbia University. He is the Director of the Center for Topology of Cancer Evolution and Heterogeneity. Dr. Rabadan received his PhD in Theoretical Physics and went on to conduct research in that field at the European Laboratory for Particle Physics (CERN) in Switzerland, and at the Institute for Advanced Study (IAS) in Princeton. In 2008 he joined the faculty at Columbia University, where he is currently a Professor in the Departments of Systems Biology and Biomedical Informatics. He is the director of the Program for Mathematical Genomics and the NCI funded Columbia University Center for Topology of Cancer Evolution and Heterogeneity.

    At Columbia, he leads a highly interdisciplinary lab with researchers from the fields of mathematics, physics, computer science, engineering, and medicine, with the common goal of solving pressing biomedical problems through mathematical and computational models. Dr. Rabadan has been named one of Popular Science's Brilliant 10 (2010), a Stewart Trust Fellow (2013), and he received the Harold and Golden Lamport Award at Columbia University (2014). His work is mainly focused on developing tools to analyze genomic data, extracting the relevant information to understand the molecular biology, population genetics, evolution, and epidemiology of cancers.


1:40pm - "Dissecting human gliomas by single-cell genomics"

        • Mario L. Suvà, MD, PhD

          Assistant Professor of Pathology
          MGH Cancer Center and Harvard Medical School
          Associated Member, Broad Institute of MIT and Harvard
          Co-Director, Cancer Program, Harvard Stem Cell Institute
          Brigham and Women's Hospital and Harvard Medical School

  • View Bio

    Dr. Mario L. Suvà is a scientist and Assistant Professor in the Department of Pathology and the Center for Cancer Research at MGH and an Associate Member at the Broad Institute of Harvard and MIT. Dr. Suvàalso co-directs the Cancer Program at the Harvard Stem Cell Institute. His expertise is in neuro-oncology and single-cell genomics.

    Dr. Suvà obtained his MD and PhD in Lausanne, Switzerland, studying cancer stem cells in gliomas and sarcomas. He did his post-doctoral research at MGH with Brad Bernstein, applying chromatin analysis and functional approaches to identify master regulators of glioma stem cell programs.Dr. Suvà's laboratory focuses on diffuse gliomas in adults and children. A particular effort of the laboratory is on dissecting the heterogeneity of patient tumors and relating transcriptional and genetic programs of individual cancer cells. Suvà directed pioneering studies characterizing glioblastoma, oligodendroglioma, astrocytoma and pediatric gliomas with single-cell genomic technologies, shedding light on tumor heterogeneity, tumor classification, glioma cell lineages, cancer stem cell programs, tumor evolution and the composition of the tumor microenvironment.


2:10pm - Break


2:30pm - "Regulators of intratumor heterogeneity in breast cancer"

  • View Bio

    Dr. Kornelia Polyakis a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School and is an internationally recognized leader of the breast cancer field. Dr. Polyak’s laboratory is dedicated to the molecular analysis of human breast cancer with the goal of improving the clinical management of breast cancer patients. Her lab has devoted much effort to develop new ways to study tumors as a whole and to apply interdisciplinary approaches.

    Using these methods, Dr. Polyak’s lab has been at the forefront of studies analyzing purified cell populations from normal and neoplastic human breast tissue at genomic scale and in situ at single-cell level and to apply mathematical and ecological models for the better understanding of breast tumor evolution. Dr. Polyak has received numerous awards including the Paul Marks Prize for Cancer Research in 2011, the 2012 AACR Outstanding Investigator Award for Breast Cancer Research, and the Rosalind Franklin Award in 2016. She is also a 2015 recipient of the NCI Outstanding Investigator Award.


3:00pm - "Tumor heterogeneity and dynamics in cancer"

                • Gad Getz, PhD

                  gad getz

                  Associate Professor of Pathology
                  Director of Bioinformatics
                  Massachusetts General Hospital Cancer Center and Harvard Medical School
                  Institute Member, Broad Institute of MIT and Harvard

  • View Bio

    Dr. Gad Getz is Associate Professor of Pathology at Harvard Medical School, Director of Bioinformatics at the Massachusetts General Hospital Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of Harvard and MIT, where he directs the Cancer Genome Computational Analysis Group. He is also the Paul C. Zamecnik Chair in Oncology at the MGH Cancer Center.

    Dr. Getz’s Laboratory is focused on cancer genome analysis, which includes two major steps: (i) Characterization – cataloging of all genomic events and the mechanisms that created them during the clonal evolution of the cancer, including events at the DNA, RNA and protein levels in normal and tumor samples from an individual patient; and (ii) Interpretation – analysis of the characterization data across a cohort of patients, with the aim of identifying the alterations in genes and pathways that cause cancer or increase its risk as well as identifying mutational processes, tumor evolution and heterogeneity, molecular subtypes of the disease, their markers and relationship to clinical variables. Dr. Getz has received numerous awards including the 2017 Paul Marks Prize for Cancer Research.


3:30pm - Break


3:50pm - Keynote Speaker Introduction & Prize Presentation


4:00pm - Prize Recipient/Keynote Speaker

Keynote Address: "Tracking Cancer Evolution: adaptation, metastatic progression and immune evasion through chromosomal chaos and selection"

    • Charles Swanton, MD, PhD

      Royal Society Napier Chair in Oncology
      The Francis Crick Institute
      Chair, Personalized Cancer Medicine, UCL Hospitals
      Cancer Research-UK Lung Cancer Centre of Excellence

  • View Bio

    Dr. Charles Swanton received his MD/PhD in 1999 from the Imperial Cancer Research Fund Laboratories and completed his Cancer Research UK funded clinician/scientist medical oncology training in 2008. He combines his laboratory research at the Francis Crick Institute with clinical duties focused on biological mechanisms of cancer drug resistance. Dr. Swanton was made Fellow of the Royal College of Physicians in April 2011, and Chair in Personalized Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011. Dr. Swanton is the Chief Investigator of the CRUK TRACERx lung cancer evolution study, and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013, Fellow of the European Academy of Cancer Sciences in 2013, and Fellow of the Academy of Medical Sciences in 2015. Dr. Swanton was awarded the Jeremy Jass Prize in 2014, Stand Up to Cancer Translational Cancer Research Prize in 2015, Glaxo Smith Kline Biochemical Society Prize in recognition of distinguished research leading to new advances in medical science and the Ellison-Cliffe Medal and Lecture, Royal Society of Medicine in 2016. He was awarded the 2016 San Salvatore Foundation prize, and elected an EMBO member in 2017. Dr. Swanton was appointed Napier Professor in Cancer by the Royal Society in 2016, and Cancer Research UK’s Chief Clinician in 2017.

 

2018 Prize Recipient

  • Charles Swanton, MD, PhD

    Royal Society Napier Chair in Oncology
    The Francis Crick Institute
    Chair, Personalized Cancer Medicine, UCL Hospitals
    Cancer Research-UK Lung Cancer Centre of Excellence

Biography:

Dr. Charles Swanton received his MD/PhD in 1999 from the Imperial Cancer Research Fund Laboratories and completed his Cancer Research UK funded clinician/scientist medical oncology training in 2008. He combines his laboratory research at the Francis Crick Institute with clinical duties focused on biological mechanisms of cancer drug resistance. Dr. Swanton was made Fellow of the Royal College of Physicians in April 2011, and Chair in Personalized Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011. Dr. Swanton is the Chief Investigator of the CRUK TRACERx lung cancer evolution study, and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013, Fellow of the European Academy of Cancer Sciences in 2013, and Fellow of the Academy of Medical Sciences in 2015. Dr. Swanton was awarded the Jeremy Jass Prize in 2014, Stand Up to Cancer Translational Cancer Research Prize in 2015, Glaxo SmithKline Biochemical Society Prize in recognition of distinguished research leading to new advances in medical science and the Ellison-Cliffe Medal and Lecture, Royal Society of Medicine in 2016. He was awarded the 2016 San Salvatore Foundation prize, and elected an EMBO member in 2017. Dr. Swanton was appointed Napier Professor in Cancer by the Royal Society in 2016, and Cancer Research UK’s Chief Clinician in 2017.

Research Summary:

Image shows a heterogeneous tumor under attack by a cytotoxic T cell response with Darwin’s “I Think” diagram (1837) depicting branched evolution in the background.
PHOTO CREDIT: Courtesy of CRUK.

Dr. Charles Swanton is a physician scientist who combines his clinical trials practice at UCLH, with his scientific work on cancer genome instability and evolution, that foster drug resistance. His laboratory program is studying the branched evolutionary nature of cancer progression and metastases and investigating mechanisms that generate cell-to-cell variation that drive selection and adaptation. In order to achieve these goals, Dr. Swanton has initiated TRACERx (TRAcking Cancer Evolution through therapy/Rx), two national longitudinal cancer cohorts in renal cancer and non-small cell lung cancer. These studies aim to define the origins of the lethal sub clone or subclones across hundreds of patients, examine the relationship between tumor diversity and clinical outcome in prospective studies, elucidate whether circulating tumor biomarkers can be used to monitor branched evolution, understand the adaptive immune microenvironment over space and time, and ultimately define the cellular processes that foster cancer heterogeneity and variation. The laboratory is investigating several such processes including the role of the APOBEC cytidine deaminase in driving branched evolution in lung cancer and how the APOBEC family is activated during cancer evolution. His group studies the role of DNA replication stress and aberrant repair in initiating chromosomal instability and the cellular processes that permit the mis-segregation of chromosomes. Finally, through the analysis of the immune microenvironment, the group is investigating immune editing during cancer progression and how branched evolution is permitted through loss of HLA at sub clonal resolution. The lab is attempting to harness cancer evolution and develop therapeutic adoptive T cell approaches to target clonal/truncal neo-antigens present in every tumor cell, with the aim of optimizing tumor response and survival and limiting the capacity of tumors to acquire resistance to therapy.

Past Events

2017 Jonathan Kraft Prize for Excellence in Cancer Research

Wednesday, May 3, 2017 | Download Event Flyer

Since 2006, each year the Mass General Center for Cancer Research has honored a luminary in the field - an extraordinary scientist, who not only has made major advances in our understanding of cancer and its treatment, but also has been recognized as a true mentor by teaching and inspiring the next generation of cancer researchers.

The 2017 Kraft award was presented to Dr. Kevan M. Shokat, of UCSF, for his outstanding work in pioneering a technique to identify the substrates of individual kinases, and for developing a method to precisely control a particular kinase’s activity using small-molecule inhibitors. Previous recipients of the MGH Award in Cancer Research (preceding the endowment of this award in honor of Jonathan Kraft) include: Anton Berns, Joan Massague, Titia de Lange, Bert Vogelstein, Charles Sawyers, Michael Stratton, Craig Thompson, James Allison and Hans Clevers. In 2015 David Allis was the first recipient of the named Jonathan Kraft Award. Last year, it was awarded to Joan Steitz.


2016 Jonathan Kraft Prize for Excellence in Cancer Research

Thursday, May 26, 2016 | Download Event Flyer

The 2016 Kraft award was presented to Dr. Joan A. Steitz, of Yale University, for her outstanding contributions to the field of non-coding RNA-protein complexes and their emerging role in abnormal development and cancer.

Previous Award Recipients

Jonathan Kraft Prize for Excellence in Cancer Research

Presented by the Massachusetts General Hospital Cancer Center

2017
Kevan M. Shokat, PhD
Professor, Department of Cellular and Molecular Pharmacology
University of California San Francisco

2016
Joan A. Steitz, PhD
Sterling Professor of Molecular Biophysics and Biochemistry
Yale School of Medicine

2015
C. David Allis, MD, PhD
Joy and Jack Fishman Professor
Laboratory of Chromatin Biology and Epigenetics, Rockefeller University

The Annual MGH Award In Cancer Research

In memory of Nathan and Grace Shiff

2014
Hans Clevers, MD, PhD
President of the Royal Netherlands Academy of Arts and Sciences
Professor of Molecular Genetics, University Utrecht, Netherlands

2013
James Allison, PhD
Chair, Department of Immunology
MD Anderson Cancer Center, Houston, TX

2012
Craig Thompson, MD
President and Chief Executive Officer
Memorial Sloan-Kettering Cancer Center, New York

2011
Michael Stratton, MD, FRS
Director, Wellcome Trust Sanger Institute

2010
Charles Sawyers, MD
Chairman of the Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center, New York

2009
Bert Vogelstein, MD
Director of the Ludwig Center for Cancer Genetics & Therapeutics
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University, Maryland

2008
Titia de Lange, PhD
Associate Director of the Anderson Cancer Center
Rockefeller University, New York

2007
Joan Massague, PhD
Chairman of the Cancer Biology and Genetics Program
Memorial Sloan-Kettering Cancer Center, New York

2006
Anton Berns, PhD
Director of Research and Chairman of the Board of Directors,
Netherlands Cancer Institute and Antoni van Leewenhoek Hospital, The Netherlands

Contact

For more information regarding the Kraft Prize Symposium, please contact:

Sophia Sid
ssid@partners.org
(617) 726-6015

Back to Top